HONG KONG, Sep 29, 2025 - 28 September, The world's first 9,300 CEU methanol dual-fuel Pure Car and Truck Carrier (PCTC), "CM HONG KONG", celebrated its maiden voyage with a ceremony in Tsing Yi, Hong Kong. Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, Deputy Director of the Liaison Office of the Central People's Government in the HKSAR, Qi Bin, and Chairman of China Merchants Group Limited, Miao Jianmin, etc. attended the ceremony, with Executive Vice President of China Merchants Group Limited, Deng Renjie, as the master of ceremonies.During the event, a commemorative plaque was presented to the ship's captain. Guests toured the vessel's bridge, crew quarters, and innovative methanol dual-fuel system, witnessing its advancements in low-carbon technology and operational efficiency.Built for China Merchants Energy Shipping (CMES), "CM HONG KONG" is the first large-scale car carrier powered by a methanol dual-fuel system, enabling seamless switching between conventional fuel and methanol. Compliant with IMO Tier III emission standards, it achieves over 70% emissions reduction when using green methanol. The ship, measuring 219.9 meters long and 37.7 meters wide, has a design capacity of 9,300 CEUs, with an actual capacity of up to 9,492 CEUs. Its 78,416-square-meter loading area, equivalent to 11 football fields, features 13 decks, including three adjustable lift decks and three tailored for hydrogen fuel cell vehicles. Dual stern and side ramps boost loading/unloading efficiency by 30%. Safety is enhanced with 156 CCTV cameras and thermal imaging infrared sensors across all decks."CM HONG KONG" embarked on its inaugural China-to-Europe route, unloading vehicles in Hong Kong before heading to Europe. Leveraging Hong Kong's free port status, CMES aims to advance the "green fuel trade + port services" model, fostering economic growth, attracting international vessels for green fuel bunkering, and strengthening Hong Kong's role as a global green maritime hub.Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, delivered a speech at the ceremony.Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, delivered a speech at the ceremony.Chairman of China Merchants Group Limited, Miao Jianmin, delivered a speech at the ceremony. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - The future arrived today in Singapore as the World Quantum Summit 2025 (WQS) — themed “Quantum Unboxed: Extending the Reach of AI” — concluded at the Sheraton Towers Singapore with a full house attendance filling the ballroom to capacity. The overwhelming turnoutunderscored the growing global appetite for practical quantum solutions that extend the power of artificial intelligence and accelerate its real-world impact.This year’s summit was not a standalone event but the culmination of a three-day intensive journey into the future of computing and intelligence. On 23–24 September, participants took part in a sold-out Executive Workshop on Quantum and AI, which built foundational understanding of quantum principles, emerging architectures, and integration strategies. The final day brought it all together, showcasing how those concepts are now being deployed in industry — from real-world applications to large-scale investment strategies.Unlike traditional conferences focused solely on research or theory, WQS 2025 brought together the entire ecosystem driving quantum innovation forward. The summit featured practitioners representing different quantum approaches, policy makers, venture investors, academics, corporates, researchers, and ecosystem partners — all converging under one roof to chart the path from lab breakthroughs to industry-scale adoption. On the exhibition floor, leading players such as ST Engineering, QBoson, and TM Research & Development showcased quantum - enhanced solutions in optimisation, secure computing, and AI acceleration. Meanwhile, Gold Capital Network Partners — IMGT and IWC Management — hosted curated sessions connecting founders and investors to accelerate funding into quantum ventures poised for growth.A key highlight was the line-up of 19 world-class speakers, each offering cutting-edge insights into how quantum is transforming the AI landscape. Among them were Assoc. Prof. Mile Gu, Deputy Director of the Nanyang Quantum Hub at Nanyang Technological University; Jeremy Woo, Senior Technical Advisor at D-Wave System; Deepak Waghmare, CTO (APJC) of Dell Technologies; Ujjwal Kumar, Principal Architect, Office of the CTO at Microsoft Asia; Dr. Simon See, Senior Director and Global Head of the NVIDIA AI Technology Center; Bruno Aznar Martinez, R&D Software Developer at Keysight Technologies; Raghunath Koduvayur, CEO of RAQS Quantum; Gao Qi, Algorithm Director at QBoson; Ken Chew, CEO and Partner of IWC Management; and Tony Gu, General Partner at NGC Ventures. They were joined by Ong Yongcheng of Insignia Ventures, Dr. Amelia Tan of ST Engineering, Eric Lee of Deloitte Southeast Asia, Atsushi Sugiura of Oxford Quantum Circuits, Hidetoshi Matsumura of Fujitsu Limited, Ray Han of SAP, Duleesha Kulasooriya of Deloitte, Manisha Sharma Kohli of Google, and Simon Lawrie of AWS.Throughout the summit, a clear narrative emerged: quantum computing has moved beyond theory into strategic deployment, offering a powerful multiplier for AI. Industry leaders showcased case studies where quantum-enhanced AI is already delivering breakthrough results — from accelerating molecular simulations and optimising financial portfolios to solving supply chainchallenges previously considered intractable. Discussions highlighted how enterprises are integrating quantum capabilities directly into their AI workflows, achieving dramatic improvements in processing power, speed, efficiency, and cost-to-insight.The summit also reflected the shifting investment landscape. As quantum technologies mature, institutional and venture capital investors are moving rapidly to back companies with commercially viable products and near-term revenue potential. “Quantum is no longer the future — it’s today’s most powerful strategic edge and already seeing some real applications,” said Ken Chew, CEO of IWC Management. “The confluence of quantum and AI and their cross-synergies are powerful and those who integrate it into their AI stack early will potentially define the competitive landscape of the next decade.”By the close of the event, one message was clear: quantum will not replace AI — it will supercharge it. With practitioners, investors, policymakers, and researchers now aligned on the urgency of adoption, the era of practical quantum applications is no longer a distant vision — it is here, and it is redefining howindustries think about computation, intelligence, and innovation.The World Quantum Summit has firmly established itself as Asia’s premier platform for quantum commercialisation, bridging science, industry, and capital to accelerate real-world adoption. With its unique focus on applications over abstraction and its ability to convene the full quantum ecosystem, WQS is not just a conference — it is a catalyst for the next wave of technological transformation.Media Contact:Eric KhooConference Director, TPGI Pte Ltderic.khoo@pinnaclegroup.global+65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA).Builds on China approval and strong Phase III and real-world clinical results showing durable glucose control and safety.Positions Hong Kong as a strategic gateway for Hua Medicine’s global expansion into Southeast Asia and beyond.SHANGHAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).The acceptance of the NDA marks an important milestone in Hua Medicine’s strategy to expand beyond China, bringing its innovative, disease-modifying treatment to more patients across Asia and ultimately to global markets.With more than half a million people living with diabetes in Hong Kong and nearly 240 million across Asia, the NDA represents a significant step toward addressing one of the region’s most urgent health challenges.A first-in-class therapy with global potentialDorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients, 1) It can be used as mono-treatment for drug-naïve T2D patients, as first-line treatment, 2) When metformin hydrochloride alone has poor blood glucose control, it can be used in combination with metformin hydrochloride. Unlike conventional drugs that manage symptoms, dorzagliatin targets the root cause of blood sugar dysregulation by repairing the function of glucokinase (GK), the body’s glucose sensor. By restoring glucose sensitivity, dorzagliatin helps maintain blood sugar balance and supports long-term disease management.Results from two Phase III registration trials in China demonstrated that dorzagliatin significantly and sustainably lowered HbA1c levels, improved pancreatic β-cell function, and reduced insulin resistance, all while showing strong safety and tolerability. Findings are being further validated in ongoing real-world studies, of which some interim analysis and data were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions.Strategic gateway to new marketsHong Kong has established a comprehensive, community-based system for diabetes management and serves as a medical and financial hub for the region. Research findings from the Hong Kong Diabetes and Obesity Research Institute at The Chinese University of Hong Kong indicate that the implementation of a community-based public-private collaboration model for diabetes management provided significant benefits to the community. The advanced experience in Hong Kong is of great significance for improving the quality of life of diabetes patients, controlling the progression of the disease, and reducing the burden on the healthcare system. Once approved in Hong Kong, it will also provide clinical application of dorzagliation for the personalized management of diabetes.According to Hong Kong's former new drug approval mechanism, applicants were required to submit to the authority new drug registration certificates issued by the drug regulatory agencies of two or more recognized countries, as well as other specified relevant documents, in order to support the approval and marketing of the product. Under the newly established "1+" mechanism, after meeting requirements such as local clinical data support and having the applicable scope of the new drug endorsed by local experts, an applicant only needs to submit the approval from one (instead of the original two) reference drug regulatory authority to apply for registration of the new drug in Hong Kong. This mechanism initially applied to new drugs for the treatment of serious or rare diseases, and has been extended to all new drugs since 2024.Under the leadership of Ms. Beili Cao, Vice President of Department of Corporate Operation and Great Bay Development, Hua Medicine has conducted sufficient and in-depth communications with local clinical experts and regulatory authorities in Hong Kong, and became an early pioneer of this mechanism. The Company filed its application for registration of dorzagliatin in Hong Kong at the end of July, and the application was officially accepted by the end of September.Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine, said: “Acceptance of dorzagliatin’s NDA in Hong Kong is not only recognition of its clinical value but also a pivotal step in Hua Medicine’s international journey. Hong Kong’s unique position as a regional healthcare leader and financial hub makes it the ideal gateway for expanding dorzagliatin’s reach into Southeast Asia and beyond. We are committed to working with local doctors and partners in Hong Kong to explore dorzagliatin’s potential in both treatment and prevention of prediabetes and early-stage diabetes, ensuring more patients worldwide can benefit from this breakthrough therapy.”Dorzagliatin: A transformative T2D treatmentDorzagliatin was approved in September 2022 in China, and it was included in the country’s National Reimbursement Drug List (NRDL) as of January 1, 2024.Dorzagliatin can be used alone as a first-line therapy for newly diagnosed patients, or together with metformin when blood sugar control is inadequate. Unlike many other approved oral antidiabetes drugs, no dose adjustment is required for patients with kidney impairment. It works by repairing the body’s glucose sensor, glucokinase (GK), restoring glucose sensitivity and long-term blood sugar balance. It acts across key organs—stimulating insulin secretion in the pancreas, boosting GLP-1 secretion in the gut, and regulating glycogen in the liver. This multi-target approach addresses the root cause of Type 2 diabetes, not just its symptoms.The NDA application in Hong Kong is based on the results of two Phase III registration clinical studies conducted in China evaluating the use of dorzagliatin monotherapy and in combination with metformin for the treatment of patients with Type 2 diabetes. Two studies have shown that for two categories of T2D patients—those newly diagnosed and not yet on medication, and those who have failed to respond adequately to metformin therapy— dorzagliatin can sustainably and effectively lower patients' HbA1c levels by repairing defects in the glucose sensor function of GK, significantly reduce postprandial two-hour blood glucose levels (2h-PPG), achieve high glycemic control rates without hypoglycemia, demonstrate good safety and tolerability, and continuously improve β-cell function and reduce insulin resistance.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Sep 29, 2025 - (ACN Newswire via SeaPRwire.com) – Quantum Solutions Co., Ltd. (Tokyo Stock Exchange Code: 2338.T, “Quantum”) announced its strategic financing initiative on September 26 to issue 44 million shares to a blue-chip investor mix of three heavyweight institutions, providing the necessary permanent capital and network access to position Quantum as a potential frontrunner in the world of Ethereum (ETH) listed strategies and a showcase standout in the Tokyo stock market.For Japanese investors, this represents another significant commitment by leading US capital, following Warren Buffett’s investment in Japan’s five major trading companies. For international investors, it signals that Tokyo’s stock market is an increasingly attractive destination for global capital, welcoming new opportunities for “smart money”.Dream Team of Global Capital Aligns for Quantum, International Demand for Japanese Equities Continues to GrowQuantum’s investor line-up is a market stunner in the emerging field of crypto-linked equities. Susquehanna International Group (SIG), investing via CVI Investments, holds the capital firepower to accelerate Quantum’s ETH accumulation and expand its balance sheet for upcoming fundraising rounds. With a portfolio that includes early investments in ByteDance and Strategy Inc. (NASDAQ: MSTR), SIG is a Tokyo Stock Exchange participant, offering the robust capital infrastructure that analysts consider essential for a successful Digital Asset Treasury (DAT).Cathie Wood affirms her position as the world’s leading investor in crypto-linked equities with ARK Invest’s first direct foray into APAC-listed opportunities. In the US market, ARK has a track record for identifying category leaders such as ETH Treasury Bitmine Immersion Technologies (NYSE: BMNR) and cryptocurrency exchange Coinbase (NASDAQ: COIN). By adding Quantum, Wood extends her expertise to the Tokyo market, bringing visibility to Quantum in front of the global investing audience as the region’s most promising ETH Treasury initiative.The third participant is Hong Kong-based Integrated Asset Management (IAM), led by Mr. TC Yam. As the majority shareholder of Forbes Media, IAM’s cross-sector presence in international finance and media resources bolsters Quantum’s capital depth and reputational standing. Like ARK, IAM makes its first public investment in the Tokyo stock market, signaling growing confidence among global institutional investors in Japan's equity market.The fundraise utilizes convertible bonds and both floating and fixed strike price warrants for a total issuance of approximately 44 million shares, nearly doubling the company’s existing share capital. None of the instruments are priced at a discount, a rarity for DAT fundraises, suggesting that the incoming investors are targeting long-term growth prospects. As of market closing on September 26, the nominal value of the financing round comes to over JPY 26 billion (approx. USD 180 million), with the first tranche valued at JPY 22.1 billion (approx. USD 150 million).First ETH Treasury in Japan — A Differentiated Strategy Offering Long-Term Returns on EquityAccording to research reports by leading investment banks, the key determinants of success for listed Digital Asset strategies are robust access to capital and a team with operational blockchain expertise. Through this fundraising initiative, Quantum taps into fresh sources of capital and aligns with investors of strong reputation, prompting market expectations of long-term backing.Quantum CEO Francis B. Zhou is no newcomer to the Digital Asset industry, as one of the first institutional investors and operators in the blockchain space. In 2018, Zhou acquired the world’s second largest ETH mining facility, based in Jokkmokk, Sweden. Zhou maintains investments in early stage blockchain projects alongside film and IP holdings in his venture investment portfolio, and brings a network of experienced blockchain operators, including Head of Crypto Strategy Donny Chi.Proceeds from Quantum’s financing initiative will be used to accumulate ETH. Although BTC has demonstrated adoption as a store-of-value, ETH is the foundational asset for blockchain applications, enabling companies like Quantum to explore attractive yield-generating opportunities to drive a blend of organic and inorganic growth for the company’s core treasury and balance sheet.The appeal of yield-bearing strategies is supported by data from the US market, which indicates that listed ETH Treasuries trade at a price-to-book multiple of 7.72x, more than 3 times higher than that of listed BTC Treasuries. More remarkably, the price-to-book of ETH Treasuries is trending upwards, increasing by over 20% within the trading month of September, demonstrating that the market expectations continue to strengthen for listed ETH Treasuries as it relates to long-term returns on equity.Zhou and the Quantum Solutions team have a history of exploring growth frontiers, consequently developing industry traction in AI computing, GPU hosting, and IP gaming. This positions the company to pursue unique opportunities beyond overcrowded sectors in Real World Asset (RWA) space to potentially generate more attractive returns.With the fundraise, Quantum’s notional price-to-book multiple is estimated to be less than 30% of the market median. Assuming that the company can reach its fair value, the structure of the fundraise allows the company to rapidly accelerate its capital accumulation to reach the target of 100,000 ETH within the near term, positioning Quantum among the leading ETH Treasury companies globally.Growth Driven Policies in Japan Encourage Prospects for Long-Term Shareholder ValueConsistent government support for the blockchain industry and increasing clarity in regulations are ushering in a more investor-friendly market for Digital Assets in Japan. Whereas the US market already has ETH Treasury companies such as Bitmine (NASDAQ: BMNR) and SharpLink Gaming (NASDAQ: SBET) achieving significant market cap growth as capital market highlights, Japan lacks a similar listed benchmark. Quantum Solutions’ entry fills this gap, opening a new chapter as "Japan’s first”, and creating conditions for capital inflow and renewed market participation.This financing round, nominally valued at approximately USD 180 million, is a landmark in both the Japanese stock market as well as the crypto-linked equities space. Through the combined endorsement of SIG, ARK, and IAM, Quantum not only secures funding but also international validation under a capital structure optimized to maximize long-term shareholder value. High-profile deals of this caliber further Tokyo as an emerging destination for savvy investors. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianli International Holdings Limited (“Tianli International”) and Shenzhen Yidatong Group recently held a formal signing ceremony in Hong Kong to launch their strategic partnership. The agreement, signed at 3:00 PM on September 25th, marks the official start of a high-end international school project in the heart of Laos’s National Administrative Center.This collaboration represents far more than a commercial alliance. It is a key milestone in Tianli International’s dual strategic priorities—“Education AI” and “China International Education Going Global”—and a concrete step in response to China’s Belt and Road Education Initiative and the national blueprint China Education Modernization 2035, which calls for “a new era of educational openness.”Under the agreement, the partners will jointly develop a world-class international education complex featuring two flagship schools:Premier British Boarding School, offering a complete UK curriculum and authentic boarding traditions to nurture the next generation of global leaders from Laos and neighboring countries.Lida Chinese International School, centered on China’s national curriculum, this school will provide both general and academic Chinese tracks, establish a direct pathway to China’s top universities, and promote two-way student exchange programs.The signing ceremony drew congratulations from the China Association for Non-Government Education, which praised the project as a pioneering example of Chinese private education expanding abroad. Guests and witnesses attended from China, Laos, France, Malaysia, Gambia, and other countries.Dr. Luo Shi, Chairman and President of Tianli International, stated that the partnership is both a pivotal milestone in the group’s global strategy and a major advance in its “Education AI + China International Education Going Global” initiative. Looking ahead, the two partners plan to explore innovations in smart-campus infrastructure and AI-driven teaching, delivering high-quality, diversified education options to Southeast Asia and the wider world.Media ContactCompany: Tianli Education (HK ) LimitedContact Person: Dr. Brown FengZhaoEmail: zhaofeng@tianlieducation.com Website: https://www.tianlieducation.com/en/about/index.html Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Sept 28, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the “Trial”) of ruxolitinib cream (the “Product”) in patients with mild to moderate atopic dermatitis (AD) in China.The Trial is a randomized, double-blind, placebo-controlled, multi-centre clinical trial, with 192 patients enrolled in total, aiming to evaluate the safety and efficacy of the Product in patients with mild to moderate AD. The leading institution is Shanghai Dermatology Hospital, and the principal investigator is Professor Shi Yuling.The phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate AD in China met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with ruxolitinib cream achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P

SINGAPORE, Sept 27, 2025 - (ACN Newswire via SeaPRwire.com) - Academic Labs, the team building the first Universal Database of Knowledge for decentralized autonomous learning, has secured a strategic investment from Evergreen Profits.The announcement follows the recent listing of Academic Labs’ native token, $AAX, on Biconomy—an inflection point that broadens liquidity and participation while aligning incentives across developers, contributors, and institutional partners.What is Academic Labs?Academic Labs is architecting a transparent, interoperable knowledge layer where AI agents can autonomously learn, verify, and teach skills.By combining gamified learning, DAO-based governance, and data interoperability, the project aims to create a consensus-driven intelligence substrate that is open, verifiable, and portable across ecosystems.Since launching its MVP in January 2024, Academic Labs has seen rapid adoption—200,000 videos and challenges completed in the first month—alongside notable community and institutional engagement through hackathons and courses at QS Top 50 universities. Its Project Education initiative now supports over 20 ecosystems and reaches more than two million people worldwide.On the market front, the project recorded over $6M in first-day trading volume on Gate and completed BGA’s light incubation program under Bybit.Strategic Timing: Post-$AAX Biconomy ListingThe timing of Evergreen Profits’ investment is strategically significant. With $AAX newly listed on Biconomy, Academic Labs gains distribution that can anchor real utility: staking for curation and quality assurance, contributor rewards for challenge creation and validation, and governance participation in how the Universal Knowledge Graph is expanded and audited.Investor Fit and ComplementarityEvergreen Profits’ thesis-driven approach—built on adapting to cyclical market regimes—complements this next phase by emphasizing operational discipline, risk-aware growth, and standards that support long-term composability. Their portfolio experience across AI, data, and Web3 is expected to inform Academic Labs’ interoperability roadmap and agent-facing APIs.The investment will be directed toward three priorities.First, deepening the core protocol: advancing the Universal Knowledge Graph, extending agent APIs, and implementing on-chain verifiable credentials for proof-of-skill.Second, strengthening governance and incentives: refining DAO mechanisms for reputation, staking, and curation to ensure that knowledge ingestion and validation are transparent, auditable, and resistant to manipulation.Third, accelerating ecosystem growth: expanding university partnerships, developer programs, and cross-chain integrations so that content supply, challenge design, and agent training data scale in tandem with quality controls.What distinguishes this partnership is its emphasis on verifiability and portability. In an environment increasingly shaped by agentic AI, the bottleneck is not model capacity but trustworthy, structured knowledge and the signals that govern its use.By coupling $AAX’s broadened liquidity with Evergreen Profits’ cycle-aware capital and operational guidance, Academic Labs aims to turn raw educational content into an on-chain, consensus-curated knowledge asset that AI agents can query, learn from, and contribute back to—while users retain visibility into provenance and incentives.About Academic LabsAcademic Labs is building the 1st Universal Database of Knowledge that empowers decentralized autonomous learning for AI agents that assist users in acquiring skills and knowledge, fostering consensus-based intelligence for all of human society. Through gamification, DAOs, and data interoperability, we offer a limitless, transparent, and personalized channel for sharing and learning various skills.Trade AAX: https://www.biconomy.com/exchange/AAX_USDTSocial LinksX: https://x.com/Acad_LabsTelegram Group: https://t.me/academic_labsLinktree: https://linktr.ee/academic_labsDiscord: https://discord.gg/academic-labsMedia ContactBrand: Academic LabsContact: Media teamWebsite: https://acad.live Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com